Commercially available liquid biopsy data may be misleading

A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market them — to have high clinical sensitivity and specificity in the identification of specific genetic markers associated with high-risk forms of prostate cancer. … READ MORE …

The role of the phi test prior to decisions about prostate biopsies

Yesterday morning, a newly published paper was brought to my attention. It reports that use of the Prostate Health Index or phi test in a partially prospective study can and did change urologists’ opinions about whether selected patients really do or don’t need to have a prostate  biopsy. … READ MORE …

What do urologists think about using MRI in prostate cancer diagnosis and management today?

Staff at the Urologic Oncology Branch of the National Cancer Institute have just published the results of a survey evaluating current knowledge of (some) specialist urologists and urologic oncologists about the roles of MRI scanning in the diagnosis of prostate cancer and how they are integrating the use of MRI scanning and MR-guided biopsies into their clinical practice. … READ MORE …

“The best” type of biopsy using mpMRI guidance to target the lesions

There have been suggestions that guided biopsies on the basis of multiparametric MRI (mpMRI) data are most accurate when done using so-called “in-bore” or “in-gantry” biopsies as opposed to mpMRI/TRUS fusion-guided biopsies. … READ MORE …

Does Test X change what physicians actually do and say to their patients?

One of the key ways in which we can (and do) assess the “value” of new types of medical test is by the degree to which they actually change the ways physicians act on the data and make decisions and/or recommendations about patient management. … READ MORE …

Who really needs to be given a prostate biopsy?

A newly published article in Reviews in Urology argues that, on economic grounds alone, the majority of patients thought to be at risk for prostate cancer should have a 4KScore test prior to them being given a biopsy since this test can rule out the need for biopsies with a high degree of accuracy. … READ MORE …

The evolution of evaluation of risk for clinically significant prostate cancer

Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective … READ MORE …